Ten years of research progress and what's to come

Tuberculosis

Volumn 83, Issue 1-3, 2003, Pages 77-81

  Young, Douglas B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; LIVE VACCINE;

AWARENESS; BACTERIAL GENOME; BCG VACCINATION; CELLULAR IMMUNITY; CONFERENCE PAPER; DATA BASE; EPIDEMIOLOGY; GENETIC MANIPULATION; HUMAN; MEDICAL RECORD; MEDICAL RESEARCH; MOLECULAR EVOLUTION; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0038520846     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(02)00081-1     Document Type: Conference Paper

References (29)

1. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44.
2. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the Leprosy bacillus. Nature 2001;409:1007-11.
3. http://www.tigr.org/tigr.scripts/CMR2/GenomePage3.spl?database=gmt
4. http://www.sanger.ac.uk/Projects/M_bovis/
5. http://www.tigr.org/tdb/mdb/mdbinprogress.html
6. Heym B, Honore N, Truffot-Pernot C, et al. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 1994;344:293-8.
7. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA finger-printing: recommendations for a standardized methodology. J Clin Microbiol 1993;31:406-9.
8. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis 2002;185:401-4.
9. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-9.
10. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-9.
11. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 1997;94:9869-74.
12. Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 2002;99:3684-9.
13. Glickman MS, Jacobs Jr WR. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 2001;104:477-85.
14. Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB. Purification and characterization of a tow-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 1995;63:1710-7.
15. Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001;357:2017-21.
16. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, Small PM. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284:1520-3.
17. Orme IM, McMurray DN, Belisle JT. Tuberculosis vaccine development: recent progress. Trends Microbiol 2001;9:115-8.
18. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000;97:13853-8.
19. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992;89:12013-7.
20. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted alpha beta+T cells. Nature 1994;372:691-4.
21. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-6.
22. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002;20:581-620.
23. Hill AVS. The immunogenetics of human infectious diseases. Annu Rev Immunol 1998;16:593-617.
24. http://www.who.int/tdr/diseases/tb/tbdi.htm
25. Dye C, Watt CJ, Bleed D. Low access to a highly effective therapy: A challenge for international tuberculosis control. Bull WHO 2002;80:437-44.
26. Global Alliance for TB Drug Development. Scientific Blueprint for Tuberculosis Drug Development, Tuberculosis 2001;81(Suppl 1):1-52.
27. McKinney JD, Honer zu Bentrup K, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-8.
28. Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, Andersen P. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002;70:672-8.
29. Black G F, Weir RE, Floyd S, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002;359:1393-401.